Inhibiting the VEGF–VEGFR pathway in angiosarcoma, epithelio... : Current Opinion in
Oncology Inhibiting the VEGF–VEGFR pathway in angiosarcoma, epithelioid …

Background: Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the
treatment of patients with selective subtypes of advanced soft tissue sarcoma (STS) who …

Purpose The aim of this randomized, phase II trial was to explore the activity and safety of
adding bevacizumab to paclitaxel once per week in treatment of angiosarcomas (AS) …

Epithelioid hemangioendothelioma (EHE) is an extremely rare vascular sarcoma with a very
heterogeneous presentation and prognosis. We here present five cases of EHE …

Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been
used extensively in children following solid organ transplantation, has been demonstrated to …

Background: Epithelioid haemangioendothelioma (EHE) is a rare vascular tumour, which
can arise at any site. There is little published data about the management of these tumours …

Angiosarcoma is a rare and aggressive vascular malignancy with a poor prognosis. There is
no standard chemotherapy regime for advanced angiosarcoma. Here, we report a case of …

Interventions: The patient underwent pulmonary lobectomy, but subsequently developed
multiple metastases. Within the tumor, CD31, CK, and Vimentin were found to be positive …

Simple Summary Near-infrared imaging of tumors during surgery facilitates the oncologic
surgeon to distinguish malignant from healthy tissue. The technique is based on fluorescent …

Background We report here a correlation analysis conducted along with a phase II trial
assessing bevacizumab in combination with weekly paclitaxel. Methods Circulating pro/anti …